First-quarter 2017 biopharma financing reached $6.8 billion, a 29% decrease from Q4 2016's $9.6 billion. This change can be attributed to declines across all but two deal types. (See Exhibit 1.) The "Other" financings category was significantly higher in Q1 with $2.5 billion (vs. $227 million in Q4), thanks mostly to Perrigo Co. PLC's sale of its royalty stream for the multiple sclerosis drug Tysabri (natalizumab) to RPI Finance Trust (Royalty Pharma) for $2.2 billion. [See Deal] This was Q1's largest transaction and made up 32% of the quarter's aggregate dollars.
Biopharma Quarterly Deal-Making Statistics, Q1 2017
A look at financing, M&A and alliance activity January–March 2017
Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.
More from Deal-Making
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
• By
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
• By
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
More from In Vivo
• By
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.